copd-studies-and-solutions
Home NIV in COPD | ResMed

COPD fact and figures

Chronic obstructive pulmonary disease (COPD) is the world's 4th leading cause of deaths.1

251 milllion people  live with  COPD  worldwide.2

COPD is a major cause of hospital admissions.3

The annual cost of COPD is estimated at €48.4 billion in Europe alone.4

COPD also affects patient's quality of life reducing their ability to stay active.5

Around the world

leading cause of death by 2030.6

COPD Deaths expected to increase by 30% in the coming years.7

First symptoms appear at around 40 years.8

Higher mortality rate among women.9

       comorbidities per patient.10       

 

Emerging studies demonstrate the benefits of home NIV

 

Recent evidence indicates that treatment with home non-invasive ventilation (NIV) has benefits for COPD patients with chronic stable hypercapnia.  

The HOT-HMV study

The combined outcomes of the HOT-HMV trial and accompanying health economic analysis conducted in the UK show that HOT plus home NIV is both clinically efficacious and cost-effective11, 12.

Learn More

The HOmeVent registry

The HOmeVent registry has shown that 10% of the stage 3 & 4 COPD patients seen in routine practice are chronically hypercapnic and might therefore benefit from long-term home NIV.13

Learn More

Home NIV solutions

 

ResMed connected home NIV solutions can be used to effectively manage and monitor COPD patients at home.

Home NIV solutions

 

ResMed connected home NIV solutions can be used to effectively manage and monitor COPD patients at home.

Lumis™

Lumis provides personalised home NIV for non-dependent patients and features built-in wireless connectivity to AirViewTM 

Discover More

Stellar™

Stellar is an invasive and non-invasive ventilator for non-dependent patients with changing ventilatory needs and progressive respiratory conditions. Wireless connectivity to AirView is available for Stellar through the ResMed Connectivity Module (RCM). 

Discover More

Comfortable masks for NIV

ResMed offers a wide range of hospital and homecare masks that are designed for comfort, lightness and minimal face coverage.

Discover More

AirView™

AirView allows you to see ventilated patients’ device and therapy statistics at a glance*. You can monitor your patients’ device settings remotely (unintentional leaks, respiratory rate, spontaneous trigger, minute ventilation, etc).  

Discover More

ResScan™

ResScan patient data management software provides clinicians with an easy way to record summary and high resolution data. This breath-by-breath data stream provides valuable insight into the COPD patient’s treatment.

Discover More

References

  1. Global Initiative for Chronic Obstructive Lung Disease, Pocket Guide to COPD Diagnosis, Management and Prevention, 2018 report https://goldcopd.org/wp-content/uploads/2018/02/WMS-GOLD-2018-Feb-Final-to-print-v2.pdf (accessed August 31, 2018)
  2.  World Health Organization. https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd) (accessed January 31, 2019) 
  3. National Clinical Guideline Centre (UK). Chronic Obstructive Pulmonary Disease: Management of Chronic Obstructive Pulmonary Disease in Adults in Primary and Secondary Care. Royal College of Physicians (UK) 2010;  https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0033903/pdf/PubMedHealth_PMH0033903.pdf (accessed August 31, 2018).
  4. European Lung White Book: the economic burden of lung disease. The European Lung Foundation (ELF) and the European Respiratory Society (ERS).www.erswhitebook.org/chapters/the-economic-burden-of-lung-disease (accessed August 31, 2018).
  5. Margarethe E. Wacker et al., Assessing health-related quality of life in COPD: comparing generic and disease-specific instruments with focus on comorbidities. BMC Pulmonary Medicine, 2016, DOI 10.1186/s12890-016-0238-9 https://bmcpulmmed.biomedcentral.com/articles/10.1186/s12890-016-0238-9 (accessed February 20, 2019).
  6. WHO, Chronic obstructive pulmonary disease (COPD) who.int/respiratory/copd/en/ (accessed August 31, 2018).
  7. WHO, Burden of COPD. http://www.who.int/respiratory/copd/burden/en (accessed August 31, 2018).
  8. COPD | National Heart, Lung, and Blood Institute (NHLBI). https://www.nhlbi.nih.gov/health-topics/copd#Risk-Factors. (Accessed: May 4, 2018).
  9. Laviolette, Louis et al. “Chronic Obstructive Pulmonary Disease in Women.” Canadian Respiratory Journal: Journal of the Canadian Thoracic Society 14.2 (2007) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676379/ (accessed August 31, 2018).
  10.  Dal Negro RW, Bonadiman L & Turco P Prevalence of different comorbidities in COPD patients by gender and GOLD stage. doi:10.1186/s40248-015-0023-2.
  11. Murphy P et al. Effect of Home Noninvasive Ventilation With Oxygen Therapy vs OxygenTherapy Alone on Hospital Readmission or Death After an Acute COPD Exacerbation.A Randomized Clinical Trial, JAMA. Published online May 21, 2017. doi:10.1001/jama.2017.4451.
  12. Murphy PB et al. Cost-Effectiveness of Home Oxygen Therapy-Home Mechanical Ventilation (HOT-HMV) for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)with Chronic Hypercapnic Respiratory Failure Following an Acute Exacerbation of COPD in the United Kingdom (UK). American Journal of Respiratory and Critical Care Medicine2018;197:A2517
  13. Dreher M et al. Registry of Stable Hypercapnic Chronic Obstructive Pulmonary Disease Treated With Non-Invasive Ventilation - HOmeVent Registry. ATS, San Diego, 2018. ClinicalTrials.gov Identifier: NCT02811588
    * With Stellar, therapy data is updated once a day. With Lumis, data is available one hour after the end of each therapy session.